Pre-treatment assessment should include: BMI calculation and confirmation of eligibility criteria (BMI 30 kg/m or 27 kg/m with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia) Medical history review , including thyroid disease, pancreatitis, gallbladder disease, and cardiovascular risk factors Current medications , particularly antidiabetic agents that may require dose adjustment Pregnancy status and contraception counselling where relevant (Wegovy should not be used during pregnancy and should be discontinued at least 2 months before planned conception) [12] [13] Baseline investigations : HbA1c (if diabetic or at risk), lipid profile, liver function tests, and thyroid function tests as clinically indicated Discussion of realistic expectations : Wegovy is most effective when combined with lifestyle modifications, not as monotherapy Dosing schedule follows a gradual escalation protocol to minimise gastrointestinal side effects: Weeks 14: 0.25 mg once weekly Weeks 58: 0.5 mg once weekly Weeks 912: 1 mg once weekly Weeks 1316: 1.7 mg once weekly Week 17 onwards: 2.4 mg once weekly (maintenance dose) If patients experience intolerable side effects, the dose escalation may be delayed
The three vials that arrived failed visual authenticity checks on 59 to 63 percent of packaging criteria, exceeded labeled semaglutide content by 28.56 to 38.69 percent on quantitative LC-MS analysis, measured only 7.7 to 14.37 percent purity against a 99 percent label claim, and tested positive for bacterial endotoxin in every sample at 2.1645 to 8.9511 endotoxin units per milligram
Initial Effects Diabetes Management : Improvements in blood sugar levels can often be seen within the first one to two weeks of starting semaglutide
Some patients resume weight loss by staying at current dose longer or with minor adjustments
